Dominari Holdings Inc.
DOMH
Dominari Holdings Inc., a biotechnology company, focuses on developing small-molecule anti-cancer therapeutics. The company's pipeline of therapeutics includes therapies for prostate cancer, pancreatic cancer, acute myeloid leukemia (AML), and acute lymphoblastic leukemia. It is developing DHA-dFdC, a pancreatic drug candidate; and KPC34, a small molecule treatment for acute myeloid leukemia and aā¦ read more
Healthcare
Biotechnology
45 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$4.76
Price+2.59%
$0.12
1Y
Price
Market Cap
$72.933m
Small
Price/Earnings 3y Avg5y Avg
-
Premium
Premium
Financials Overview
Key metrics over the past few years-56.4%
EBITDA Margin+48.7%
Net Profit Margin-1.0%
Free Cash Flow MarginRevenue
$52.812m
+191.0%
1y CAGR+327.0%
3y CAGR+245.3%
5y CAGREarnings
-$19.020m
-29.4%
1y CAGR+15.7%
3y CAGR-102.6%
5y CAGREPS
-$301,506.03
-12668220.6%
1y CAGR-4222711.8%
3y CAGR-3167135.3%
5y CAGRBook Value
$88.600m
$109.338m
Assets$20.738m
Liabilities$2.860m
DebtDebt to Assets
2.6%
-
Debt to EBITDAFree Cash Flow
-$7.051m
+53.4%
1y CAGR+1.5%
3y CAGR-16.9%
5y CAGRFinancial Reports
Earnings and other important metrics. Amounts in USD.No items found.
Press Releases
Statements and updates from the company